Sygnature Discovery Launches Strategic Rebrand as Global Drug Discovery CRO

Sygnature Discovery, a leading drug discovery contract research organisation (CRO), announced a strategic brand relaunch on February 16, 2026, including a new website, cementing its position as a global drug discovery partner. The rebrand positions Sygnature as the only CRO offering full Design, Make, Test, Analyze (DMTA) capabilities under one roof in both North America and Europe.

For more than 20 years, Sygnature has built a strong reputation for delivering high quality candidates. Continued investment and strategic acquisitions have enabled the company to support customers across the full drug discovery process, from target identification to candidate nomination. Sygnature is now targeting increased awareness and market share on a global scale.

Over recent years, Sygnature has integrated several complementary businesses, strengthening its scientific breadth, scale and geographic footprint. Today, its capabilities span bioscience, protein science & structural biology, synthetic & medicinal chemistry, computer-aided drug design, drug metabolism & pharmacokinetics (DMPK), in vivo pharmacology, and form & formulation, all delivered through co-located, multidisciplinary teams.

The CEO stated that biotech and pharma companies are facing volatile investment conditions, tighter timelines and rising costs. The company's truly integrated approach is built around helping customers navigate that reality — whether they're outsourcing a whole programme or need expert input in a single discipline. By bringing together multidisciplinary expertise in co-located teams, supported by AI and automation, the company helps customers move faster and improve the quality of their decisions.

Sygnature employs 700+ scientists from over 50 countries, working across Europe and North America. With no competing internal programs, the company offers total confidentiality and commitment. Over the past 20 years, the company has delivered 60+ advanced candidates, 200+ patents filed, and 200+ active projects. Over 90% of customers choose to stay with Sygnature — from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges.